PL2676953T3 - Sól hemifumaranowa kwasu 1-[4-[1-(4-cykloheksylo-3-trifluorometylobenzyloksyimino)-etylo]-2-etylobenzylo]-azetydyno-3-karboksylowego - Google Patents

Sól hemifumaranowa kwasu 1-[4-[1-(4-cykloheksylo-3-trifluorometylobenzyloksyimino)-etylo]-2-etylobenzylo]-azetydyno-3-karboksylowego

Info

Publication number: PL2676953T3
Authority: PL; Poland
Prior art keywords: ethyl; benzyloxyimino; azetidine; trifluoromethyl; cyclohexyl
Prior art date: 2008-12-18

Application number

PL13177190T

Other languages

English (en)

Inventor

Lech Ciszewski

La Cruz Marilyn De

Piotr H. Karpinski

Michael Mutz

Christian Riegert

Caspar Vogel

Ricardo Sschneeberger

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-12-18

Filing date

2009-12-16

Publication date

2017-09-29

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42236293&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2676953(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-12-16 Application filed by Novartis Ag filed Critical Novartis Ag

2017-09-29 Publication of PL2676953T3 publication Critical patent/PL2676953T3/pl

Links

KIHYPELVXPAIDH-UHFFFAOYSA-N 1-[[4-[n-[[4-cyclohexyl-3-(trifluoromethyl)phenyl]methoxy]-c-methylcarbonimidoyl]-2-ethylphenyl]methyl]azetidine-3-carboxylic acid Chemical compound CCC1=CC(C(C)=NOCC=2C=C(C(C3CCCCC3)=CC=2)C(F)(F)F)=CC=C1CN1CC(C(O)=O)C1 KIHYPELVXPAIDH-UHFFFAOYSA-N 0.000 title 1
201000010099 disease Diseases 0.000 title 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
210000004698 lymphocyte Anatomy 0.000 title 1
230000001404 mediated effect Effects 0.000 title 1
150000003839 salts Chemical class 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/15—Fumaric acid
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Transplantation (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Neurology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Pulmonology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

PL13177190T 2008-12-18 2009-12-16 Sól hemifumaranowa kwasu 1-[4-[1-(4-cykloheksylo-3-trifluorometylobenzyloksyimino)-etylo]-2-etylobenzylo]-azetydyno-3-karboksylowego PL2676953T3 (pl)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US20305308P	2008-12-18	2008-12-18

Publications (1)

Publication Number	Publication Date
PL2676953T3 true PL2676953T3 (pl)	2017-09-29

Family

ID=42236293

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PL13177190T PL2676953T3 (pl)	2008-12-18	2009-12-16	Sól hemifumaranowa kwasu 1-[4-[1-(4-cykloheksylo-3-trifluorometylobenzyloksyimino)-etylo]-2-etylobenzylo]-azetydyno-3-karboksylowego
PL09793413T PL2379497T3 (pl)	2008-12-18	2009-12-16	Sól hemifumaranowa kwasu 1-[4[1-(4-cykloheksylo-3trifluorometylobenzyloksyimino)etylo]2-etylobenzylo]-azetydyno-3-karboksylowego

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PL09793413T PL2379497T3 (pl)	2008-12-18	2009-12-16	Sól hemifumaranowa kwasu 1-[4[1-(4-cykloheksylo-3trifluorometylobenzyloksyimino)etylo]2-etylobenzylo]-azetydyno-3-karboksylowego

Country Status (35)

Country	Link
US (7)	US20120115840A1 (pl)
EP (2)	EP2379497B1 (pl)
JP (1)	JP5627597B2 (pl)
KR (5)	KR101885052B1 (pl)
CN (2)	CN104803902A (pl)
AR (3)	AR074694A1 (pl)
AU (1)	AU2009335924B2 (pl)
BR (1)	BRPI0923176B8 (pl)
CA (2)	CA2951479A1 (pl)
CL (1)	CL2011001490A1 (pl)
CO (1)	CO6390104A2 (pl)
CY (2)	CY1114662T1 (pl)
DK (2)	DK2379497T3 (pl)
EC (1)	ECSP11011210A (pl)
ES (2)	ES2436197T3 (pl)
HR (2)	HRP20131106T1 (pl)
HU (1)	HUE034819T2 (pl)
IL (3)	IL253845B (pl)
JO (1)	JO2894B1 (pl)
LT (1)	LT2676953T (pl)
MA (1)	MA32961B1 (pl)
MX (1)	MX2011006609A (pl)
MY (1)	MY152669A (pl)
NZ (1)	NZ593061A (pl)
PE (2)	PE20142374A1 (pl)
PL (2)	PL2676953T3 (pl)
PT (2)	PT2676953T (pl)
RS (2)	RS53041B (pl)
RU (1)	RU2518114C3 (pl)
SG (1)	SG171785A1 (pl)
SI (2)	SI2676953T1 (pl)
TW (2)	TWI591055B (pl)
UY (1)	UY32330A (pl)
WO (1)	WO2010080409A1 (pl)
ZA (1)	ZA201103709B (pl)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BR112013017302B1 (pt)	2011-01-07	2021-12-07	Novartis Ag	Composição farmacêutica em fase sólida
WO2012095853A1 (en)	2011-01-10	2012-07-19	Novartis Pharma Ag	Modified release formulations comprising sip receptor modulators
CN106163502B (zh)	2014-04-10	2020-12-01	诺华股份有限公司	免疫抑制剂配方
MX2016013245A (es) *	2014-04-10	2017-01-16	Novartis Ag	Regimen de dosificacion de liberacion inmediata de moduladores s1p.
WO2016135644A1 (en)	2015-02-26	2016-09-01	Novartis Ag	Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
WO2017120124A1 (en)	2016-01-04	2017-07-13	Auspex Pharmaceuticals, Inc.	Azetidine modulators of the sphingosine 1-phosphate receptor
US11434200B2 (en)	2017-03-09	2022-09-06	Novartis Ag	Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof
US11958805B2 (en) *	2017-03-09	2024-04-16	Novartis Ag	Solid forms comprising an oxime ether compound, compositions and methods of use thereof
US11629124B2 (en)	2017-03-09	2023-04-18	Novartis Ag	Solid forms comprising an oxime ether compound, compositions and methods of use thereof
US11628137B2 (en) *	2017-09-27	2023-04-18	Novartis Ag	Parenteral formulation comprising siponimod
CN111405897A (zh)	2017-09-27	2020-07-10	雷迪博士实验室有限公司	辛波莫德、其盐及其固态形式的制备方法
MX2020007268A (es) *	2017-09-29	2020-08-17	Novartis Ag	Regimen de dosificacion de siponimod.
AU2018343239A1 (en) *	2017-09-29	2020-03-12	Novartis Ag	Dosing regimen of siponimod
EP3743405B1 (en)	2018-01-22	2023-11-15	Teva Pharmaceuticals International GmbH	Crystalline siponimod fumaric acid and polymorphs thereof
CN110776450B (zh) *	2018-07-27	2022-09-27	广东东阳光药业有限公司	一种辛波莫德晶型及其制备方法
KR20200072795A (ko)	2018-12-13	2020-06-23	고려대학교 산학협력단	옥시이미노메틸벤젠 유도체를 유효성분으로 포함하는 일주기 연관성 질환의 예방 또는 치료용 약학적 조성물
CN111484434A (zh) *	2019-01-29	2020-08-04	东莞市东阳光仿制药研发有限公司	一种辛波莫德晶型及其制备方法
WO2020161632A1 (en) *	2019-02-07	2020-08-13	Dr. Reddy’S Laboratories Limited	Crystalline solid forms of siponimod
WO2020174408A1 (en) *	2019-02-27	2020-09-03	Dr. Reddy's Laboratories Limited	Solid state forms of siponimod
JP7604387B2 (ja) *	2019-03-28	2024-12-23	ファースト・バイオセラピューティクス・インコーポレイテッド	ベンゾチアゾール化合物の薬学的塩、多形体及びその製造方法
EP3972954A1 (en)	2019-05-21	2022-03-30	Synthon B.V.	Siponimod maleic acid and fumaric acid salt
AU2020372647B2 (en)	2019-10-31	2026-02-05	Idorsia Pharmaceuticals Ltd	Combination of a CXCR7 antagonist with an S1P1 receptor modulator
GB202002560D0 (en) *	2020-02-24	2020-04-08	Johnson Matthey Plc	Crystalline forms of voxelotor, and processes for the preparation thereof
WO2021240547A2 (en) *	2020-05-29	2021-12-02	Cipla Limited	Methods for the preparation of sphingosine 1-phosphate receptor modulators and solid forms thereof
CN116456977A (zh) *	2020-09-25	2023-07-18	斯索恩有限公司	西尼莫德盐和共晶
WO2022064007A1 (en)	2020-09-25	2022-03-31	Synthon B.V.	Siponimod salts and cocrystals
CN112402610A (zh) *	2020-11-20	2021-02-26	睿阜隆(杭州)生物医药有限公司	1-磷酸鞘氨醇受体调节剂在制备治疗糖尿病的药物中的新用途
WO2022127863A1 (zh) *	2020-12-16	2022-06-23	苏州晶云药物科技股份有限公司	一种羧酸类化合物半富马酸盐的晶型及其制备方法
WO2022199865A1 (en)	2021-03-26	2022-09-29	Olon S.P.A.	Novel crystalline compound of siponimod hemifumarate
EP4212156A1 (en)	2022-01-13	2023-07-19	Abivax	Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL86632A0 (en)	1987-06-15	1988-11-30	Ciba Geigy Ag	Derivatives substituted at methyl-amino nitrogen
ES2073868T3 (es) *	1991-06-04	1995-08-16	Fujisawa Pharmaceutical Co	Una composicion profilactica/terapeutica para la pleuroneumonia del cerdo.
NZ243082A (en)	1991-06-28	1995-02-24	Ici Plc	4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
AU661533B2 (en)	1992-01-20	1995-07-27	Astrazeneca Ab	Quinazoline derivatives
TW225528B (pl)	1992-04-03	1994-06-21	Ciba Geigy Ag
BR9207175A (pt)	1992-10-28	1995-12-12	Genentech Inc	Composição contendo antagonista de fator de crescimento de célula endotelial vascular sequência aminoácida de anticorpo monoclonal polipeptídeo e método de tratamento de tumor em mamífero
US5695459A (en) *	1993-06-08	1997-12-09	Hisamitsu Pharmaceutical Co., Inc.	Iontophoresis system
GB9314893D0 (en)	1993-07-19	1993-09-01	Zeneca Ltd	Quinazoline derivatives
US5362718A (en)	1994-04-18	1994-11-08	American Home Products Corporation	Rapamycin hydroxyesters
MX9707453A (es)	1995-03-30	1997-12-31	Pfizer	Derivados de quinazolina.
GB9508538D0 (en)	1995-04-27	1995-06-14	Zeneca Ltd	Quinazoline derivatives
US5747498A (en)	1996-05-28	1998-05-05	Pfizer Inc.	Alkynyl and azido-substituted 4-anilinoquinazolines
US5880141A (en)	1995-06-07	1999-03-09	Sugen, Inc.	Benzylidene-Z-indoline compounds for the treatment of disease
MX9800215A (es)	1995-07-06	1998-03-31	Novartis Ag	Pirrolopirimidas y procesos para su preparacion.
US5760041A (en)	1996-02-05	1998-06-02	American Cyanamid Company	4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en)	1996-02-14	1996-04-10	Zeneca Ltd	Quinazoline derivatives
DK0916651T3 (da) *	1996-04-04	2003-12-01	Sankyo Co	Phenylalkylcarboxylsyrederivater
HU228446B1 (en)	1996-04-12	2013-03-28	Warner Lambert Co	Kinazoline derivatives as irreversible inhibitors of protein-kinase, pharmaceutical compositions containing these compounds and use thereof
US5795909A (en) *	1996-05-22	1998-08-18	Neuromedica, Inc.	DHA-pharmaceutical agent conjugates of taxanes
EP0907642B1 (en)	1996-06-24	2005-11-02	Pfizer Inc.	Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases
US6258823B1 (en)	1996-07-12	2001-07-10	Ariad Pharmaceuticals, Inc.	Materials and method for treating or preventing pathogenic fungal infection
DE19638745C2 (de)	1996-09-11	2001-05-10	Schering Ag	Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR)
CA2265630A1 (en)	1996-09-13	1998-03-19	Gerald Mcmahon	Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders
EP0837063A1 (en)	1996-10-17	1998-04-22	Pfizer Inc.	4-Aminoquinazoline derivatives
CO4950519A1 (es)	1997-02-13	2000-09-01	Novartis Ag	Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
CO4940418A1 (es)	1997-07-18	2000-07-24	Novartis Ag	Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
TW557297B (en)	1997-09-26	2003-10-11	Abbott Lab	Rapamycin analogs having immunomodulatory activity, and pharmaceutical compositions containing same
GB9721069D0 (en)	1997-10-03	1997-12-03	Pharmacia & Upjohn Spa	Polymeric derivatives of camptothecin
ATE459616T1 (de)	1998-08-11	2010-03-15	Novartis Ag	Isochinoline derivate mit angiogenesis-hemmender wirkung
UA71587C2 (uk)	1998-11-10	2004-12-15	Шерінг Акцієнгезелльшафт	Аміди антранілової кислоти та їхнє застосування як лікарських засобів
GB9824579D0 (en)	1998-11-10	1999-01-06	Novartis Ag	Organic compounds
WO2000037502A2 (en)	1998-12-22	2000-06-29	Genentech, Inc.	Vascular endothelial cell growth factor antagonists and uses thereof
WO2000059509A1 (en)	1999-03-30	2000-10-12	Novartis Ag	Phthalazine derivatives for treating inflammatory diseases
WO2002053538A1 (en) *	2000-12-29	2002-07-11	Pfizer Limited	Amlodipine fumarate
US20030124028A1 (en) *	2001-08-10	2003-07-03	Carlson Eric D.	Apparatuses and methods for creating and testing pre-formulations and systems for same
US7927613B2 (en) *	2002-02-15	2011-04-19	University Of South Florida	Pharmaceutical co-crystal compositions
AU2003235435A1 (en) *	2002-03-20	2003-10-08	Teva Pharmaceutical Industries Ltd.	Crystalline forms of quetiapine hemifumarate
US6900206B2 (en) *	2002-06-20	2005-05-31	Bristol-Myers Squibb Company	Indole, azaindole and related heterocyclic sulfonylureido piperazine derivatives
DE10315917A1 (de) *	2003-04-08	2004-11-18	Schwarz Pharma Ag	Hochreine Basen von 3,3-Diphenylpropylaminmonoestern
MY150088A (en) *	2003-05-19	2013-11-29	Irm Llc	Immunosuppressant compounds and compositions
WO2004110330A1 (en)	2003-06-13	2004-12-23	Stephen Dichiera	Adjustable bed support and bed
AR051444A1 (es) *	2004-09-24	2007-01-17	Centocor Inc	Proteinas derivadas de inmunoglobulina especifica de il-23p40, composiciones, epitopos, metodos y usos
KR20140095109A (ko) *	2004-11-29	2014-07-31	노파르티스 아게	Ｓ１ｐ 수용체 효능제의 투여 용법
AU2006278596A1 (en) *	2005-08-04	2007-02-15	Novartis Ag	Salts of vildagliptin
GT200600350A (es) *	2005-08-09	2007-03-28		Formulaciones líquidas
US20060223820A1 (en) *	2006-03-21	2006-10-05	Chemagis Ltd.	Crystalline aripiprazole salts and processes for preparation and purification thereof
GB0612721D0 (en) *	2006-06-27	2006-08-09	Novartis Ag	Organic compounds
NZ577320A (en) *	2006-11-07	2012-01-12	Novartis Ag	CRYSTALLINE FORMS OF ALISKIREN HEMIFUMARATE N-(3-amino-2,2-dimethyl-3-oxopropyl)-2,7-di(1-methylethyl)-4-hydroxy-5-amino-8-[4-methoxy-3-(3-methoxypropoxy)phenyl]-octanamide

2009
- 2009-12-16 PT PT131771909T patent/PT2676953T/pt unknown
- 2009-12-16 SI SI200931675A patent/SI2676953T1/sl unknown
- 2009-12-16 LT LTEP13177190.9T patent/LT2676953T/lt unknown
- 2009-12-16 HU HUE13177190A patent/HUE034819T2/en unknown
- 2009-12-16 MY MYPI20112413 patent/MY152669A/en unknown
- 2009-12-16 KR KR1020187000381A patent/KR101885052B1/ko not_active Expired - Fee Related
- 2009-12-16 JP JP2011542351A patent/JP5627597B2/ja active Active
- 2009-12-16 KR KR1020167013818A patent/KR20160064245A/ko not_active Ceased
- 2009-12-16 PL PL13177190T patent/PL2676953T3/pl unknown
- 2009-12-16 CA CA2951479A patent/CA2951479A1/en not_active Abandoned
- 2009-12-16 PE PE2014001111A patent/PE20142374A1/es not_active Application Discontinuation
- 2009-12-16 RU RU2011129222A patent/RU2518114C3/ru active Protection Beyond IP Right Term
- 2009-12-16 DK DK09793413.7T patent/DK2379497T3/da active
- 2009-12-16 KR KR1020177014691A patent/KR20170062554A/ko not_active Ceased
- 2009-12-16 CN CN201510102280.1A patent/CN104803902A/zh active Pending
- 2009-12-16 NZ NZ593061A patent/NZ593061A/xx not_active IP Right Cessation
- 2009-12-16 BR BRPI0923176A patent/BRPI0923176B8/pt active IP Right Grant
- 2009-12-16 EP EP09793413.7A patent/EP2379497B1/en active Active
- 2009-12-16 AR ARP090104917A patent/AR074694A1/es not_active Application Discontinuation
- 2009-12-16 HR HRP20131106AT patent/HRP20131106T1/hr unknown
- 2009-12-16 KR KR1020117016548A patent/KR20110096584A/ko not_active Ceased
- 2009-12-16 EP EP13177190.9A patent/EP2676953B1/en active Active
- 2009-12-16 PT PT97934137T patent/PT2379497E/pt unknown
- 2009-12-16 KR KR1020167030350A patent/KR20160129915A/ko not_active Ceased
- 2009-12-16 CN CN2009801512748A patent/CN102256943A/zh active Pending
- 2009-12-16 RS RS20130510A patent/RS53041B/sr unknown
- 2009-12-16 WO PCT/US2009/068143 patent/WO2010080409A1/en not_active Ceased
- 2009-12-16 MA MA34008A patent/MA32961B1/fr unknown
- 2009-12-16 PL PL09793413T patent/PL2379497T3/pl unknown
- 2009-12-16 MX MX2011006609A patent/MX2011006609A/es active IP Right Grant
- 2009-12-16 IL IL253845A patent/IL253845B/en unknown
- 2009-12-16 ES ES09793413T patent/ES2436197T3/es active Active
- 2009-12-16 SG SG2011036886A patent/SG171785A1/en unknown
- 2009-12-16 US US13/140,478 patent/US20120115840A1/en not_active Abandoned
- 2009-12-16 ES ES13177190.9T patent/ES2631203T3/es active Active
- 2009-12-16 IL IL294514A patent/IL294514A/en unknown
- 2009-12-16 CA CA2747437A patent/CA2747437C/en active Active
- 2009-12-16 RS RS20170599A patent/RS56110B1/sr unknown
- 2009-12-16 UY UY0001032330A patent/UY32330A/es not_active Application Discontinuation
- 2009-12-16 PE PE2011001226A patent/PE20120336A1/es not_active Application Discontinuation
- 2009-12-16 AU AU2009335924A patent/AU2009335924B2/en active Active
- 2009-12-16 DK DK13177190.9T patent/DK2676953T3/en active
- 2009-12-16 SI SI200930750T patent/SI2379497T1/sl unknown
- 2009-12-17 TW TW103142662A patent/TWI591055B/zh active
- 2009-12-17 TW TW098143443A patent/TWI500603B/zh active
- 2009-12-17 JO JO2009488A patent/JO2894B1/en active
2011
- 2011-05-20 ZA ZA2011/03709A patent/ZA201103709B/en unknown
- 2011-05-23 IL IL213071A patent/IL213071A0/en unknown
- 2011-06-17 CL CL2011001490A patent/CL2011001490A1/es unknown
- 2011-06-23 CO CO11079284A patent/CO6390104A2/es not_active Application Discontinuation
- 2011-07-15 EC EC2011011210A patent/ECSP11011210A/es unknown
2013
- 2013-06-12 US US13/915,941 patent/US20140005162A1/en not_active Abandoned
- 2013-11-20 CY CY20131101026T patent/CY1114662T1/el unknown
2015
- 2015-03-03 US US14/636,248 patent/US20150175536A1/en not_active Abandoned
2017
- 2017-06-14 HR HRP20170916TT patent/HRP20170916T1/hr unknown
- 2017-06-22 CY CY20171100669T patent/CY1119037T1/el unknown
- 2017-10-31 US US15/799,235 patent/US20180118678A1/en not_active Abandoned
2018
- 2018-07-10 AR ARP180101916 patent/AR112227A2/es unknown
2020
- 2020-11-11 US US17/095,052 patent/US20210323915A1/en not_active Abandoned
2021
- 2021-03-22 AR ARP210100712A patent/AR121635A2/es unknown
2022
- 2022-08-10 US US17/818,889 patent/US20230357142A9/en not_active Abandoned
2024
- 2024-02-06 US US18/434,514 patent/US20240239743A1/en active Pending

Also Published As

Publication number	Publication date
CA2747437C (en)	2018-08-21
BRPI0923176A2 (pt)	2016-02-16
CN104803902A (zh)	2015-07-29
EP2676953A1 (en)	2013-12-25
JP2012512881A (ja)	2012-06-07
EP2676953B1 (en)	2017-03-22
SI2379497T1 (sl)	2013-12-31
TW201509909A (zh)	2015-03-16
BRPI0923176B8 (pt)	2021-05-25
KR20160064245A (ko)	2016-06-07
AR074694A1 (es)	2011-02-02
DK2379497T3 (da)	2013-11-25
BRPI0923176B1 (pt)	2020-12-01
CL2011001490A1 (es)	2012-01-13
PL2379497T3 (pl)	2014-01-31
KR101885052B1 (ko)	2018-08-02
HRP20131106T1 (hr)	2013-12-20
BRPI0923176A8 (pt)	2017-09-12
MX2011006609A (es)	2011-06-30
LT2676953T (lt)	2017-06-26
ES2436197T3 (es)	2013-12-27
RU2011129222A (ru)	2013-01-27
TWI500603B (zh)	2015-09-21
ZA201103709B (en)	2012-01-25
CA2951479A1 (en)	2010-07-15
AU2009335924A1 (en)	2011-06-30
UY32330A (es)	2010-07-30
US20140005162A1 (en)	2014-01-02
CO6390104A2 (es)	2012-02-29
AR112227A2 (es)	2019-10-02
CA2747437A1 (en)	2010-07-15
NZ593061A (en)	2013-08-30
SI2676953T1 (sl)	2017-07-31
US20180118678A1 (en)	2018-05-03
ECSP11011210A (es)	2011-08-31
PE20120336A1 (es)	2012-04-30
MA32961B1 (fr)	2012-01-02
EP2379497A1 (en)	2011-10-26
TWI591055B (zh)	2017-07-11
KR20170062554A (ko)	2017-06-07
US20220402870A1 (en)	2022-12-22
US20120115840A1 (en)	2012-05-10
RU2518114C3 (ru)	2021-11-24
WO2010080409A1 (en)	2010-07-15
US20150175536A1 (en)	2015-06-25
HUE034819T2 (en)	2018-02-28
KR20160129915A (ko)	2016-11-09
PT2379497E (pt)	2013-11-29
PT2676953T (pt)	2017-06-29
JP5627597B2 (ja)	2014-11-19
AU2009335924B2 (en)	2012-11-08
AR121635A2 (es)	2022-06-22
CN102256943A (zh)	2011-11-23
MY152669A (en)	2014-10-31
RU2518114C2 (ru)	2014-06-10
IL294514A (en)	2022-09-01
RS53041B (sr)	2014-04-30
KR20110096584A (ko)	2011-08-30
EP2379497B1 (en)	2013-08-21
TW201035048A (en)	2010-10-01
CY1119037T1 (el)	2018-01-10
DK2676953T3 (en)	2017-07-03
KR20180006492A (ko)	2018-01-17
HK1159631A1 (en)	2012-08-03
IL253845A0 (en)	2017-09-28
SG171785A1 (en)	2011-07-28
PE20142374A1 (es)	2015-01-30
IL213071A0 (en)	2011-07-31
RS56110B1 (sr)	2017-10-31
US20240239743A1 (en)	2024-07-18
JO2894B1 (en)	2015-09-15
ES2631203T3 (es)	2017-08-29
US20230357142A9 (en)	2023-11-09
HRP20170916T1 (hr)	2017-09-22
CY1114662T1 (el)	2016-10-05
US20210323915A1 (en)	2021-10-21
IL253845B (en)	2022-08-01

Publication	Publication Date	Title
PT2676953T (pt)	2017-06-29	Sal hemifumarato de ácido 1-[4-[1-(4-ciclo-hexil-3-trifluorometil-benziloxi-imino)-etil]-2-etil-benzil]-azetidino-3-carboxílico para utilização no tratamento de doenças mediadas por linfócitos
HUS2000044I1 (hu)	2020-12-28	Proliferatív betegségek kezelésében alkalmas 1-((5-heteroariltiazol-2-il)-amino-karbonil)pirrolidin-2-karboxamid származékok, mint foszfatidilinozitol 3-kináz (P13K) inhibitorok
EP2303918A4 (en)	2012-08-15	METHOD FOR DOSED ADMINISTRATION OF A ACTIVIN ACTRIIA ANTAGONIST AND OBSERVATION OF TREATED PATIENTS
IL236726A0 (en)	2015-02-26	A method for analyzing cardiac arrhythmias
ZA201103759B (en)	2012-01-25	Pyridyloxyindoles inhibitors of vegf-r2 and use thereof for treatment of disease
ZA201006523B (en)	2011-09-28	(e)-n-(2-amino-phenyl)-3-{1-[4-(1-methyl-1h-pyrazol-4-yl)-benzenesulfonyl]-1h-prrrol-3-yl}-acrylamide salts
IL200956A (en)	2015-05-31	1– [2– (2,4 – dimethylphenylsulfonyl) –phenyl] piperazine for the treatment of pain
IL194975A0 (en)	2011-08-01	Composition and methods for treatment of congestive heart failure
IL212404A0 (en)	2011-06-30	Compounds for treating ophthalmic diseases and disorders
BRPI1007877A2 (pt)	2018-03-13	"inibidores de dpp-iv para o tratamento de diabetes em pacientes pediátricos"
IL222557A (en)	2016-09-29	A compound for use in treating mutant disorders has ruled
IL212707A0 (en)	2011-07-31	Compounds, pharmaceutical composition and methods for use in treating metabolic disorders
IL208254A0 (en)	2010-12-30	Substituted pyrrolidine and piperdine compounds derivatives thereof, and methods for treating pain
IL209816A0 (en)	2011-02-28	Combination of pilocarpin and methimazol for treating charcot-marietooth disease and related disorders
GB0915259D0 (en)	2009-10-07	Sulphur-linked compounds for treating ophthalmic diseases and disorders
ZA201008589B (en)	2012-02-29	Medicament dispenser and method
IL212924A0 (en)	2011-07-31	Hsp90 inhibitors for therapeutic treatment
GB0816650D0 (en)	2008-10-22	Therapeutic bone grwth and regeneration
IL210428A (en)	2016-05-31	Apadnosone dosing unit and method of use
HU0800775D0 (en)	2009-03-02	New yeastmushroom and process for hidrancing fruit storage disease
HK1158973A (en)	2012-07-27	Hsp90 inhibitors for therapeutic treatment
GB0811492D0 (en)	2008-07-30	rotating and telesopic patient assist bar(ratpab)
AU2008903656A0 (en)	2008-07-31	Method for improving renal function in cardiac surgery patients
HK1144810A (en)	2011-03-11	Indole compounds and methods for treating visceral pain